Влияние разных групп лекарственных средств на риск развития лекарственно-индуцированных эпилептических приступов
Влияние разных групп лекарственных средств на риск развития лекарственно-индуцированных эпилептических приступов
Остроумова Т.М., Акимова Е.С., Кочетков А.И., Остроумова О.Д. Влияние разных групп лекарственных средств на риск развития лекарственно-индуцированных эпилептических приступов. Consilium Medicum. 2020; 22 (5): 98–105.
DOI: 10.26442/20751753.2020.5.200001
________________________________________________
Ostroumova Т.М., Akimova Е.S., Kochetkov A.I., Ostroumova O.D. Impact of different medication groups on drug-induced seizures risk. Consilium Medicum. 2020; 22 (5): 98–105. DOI: 10.26442/20751753.2020.5.200001
Влияние разных групп лекарственных средств на риск развития лекарственно-индуцированных эпилептических приступов
Остроумова Т.М., Акимова Е.С., Кочетков А.И., Остроумова О.Д. Влияние разных групп лекарственных средств на риск развития лекарственно-индуцированных эпилептических приступов. Consilium Medicum. 2020; 22 (5): 98–105.
DOI: 10.26442/20751753.2020.5.200001
________________________________________________
Ostroumova Т.М., Akimova Е.S., Kochetkov A.I., Ostroumova O.D. Impact of different medication groups on drug-induced seizures risk. Consilium Medicum. 2020; 22 (5): 98–105. DOI: 10.26442/20751753.2020.5.200001
Одной из причин развития эпилептических приступов (ЭП) является воздействие тех или иных лекарственных средств. Лекарственно-индуцированные ЭП (ЛИЭП) и эпилептический статус могут также развиваться на фоне приема или отмены достаточно большого ряда препаратов. Наиболее часто возникновение ЛИЭП ассоциировано с приемом антидепрессантов, противоэпилептических препаратов, антибиотиков, противоопухолевых препаратов, опиоидных анальгетиков, анестетиков и др. Осведомленность и адекватная оценка потенциального риска развития ЛИЭП на фоне назначенных пациенту препаратов, мониторирование и коррекция факторов, определяющих и повышающих риск возникновения ЛИЭП, а также отмена или замена лекарственных средств, потенциально вызывающих ЭП, при развитии ЛИЭП, являются важнейшими лечебно-профилактическими мероприятиями, позволяющими предотвратить развитие ЛИЭП и эпилептического статуса. Ключевые слова: эпилептические приступы, лекарственно-индуцированные эпилептические приступы, нежелательные побочные реакции.
________________________________________________
One of the reasons for the development of epileptic seizures (ES) is the effect of certain drugs. Drug-induced ES and status epilepticus can also develop due to administration or withdrawal of a large number of drugs. The most common drug-induced ES are associated with the use of antidepressants, antiepileptic drugs, antibiotics, antitumor drugs, opioid analgesics, anesthetics, etc. Awareness and adequate assessment of the potential risk of the development of drug-induced ES, monitoring and correction of factors that determine and increase the risk of drug-induced ES, as well as the withdrawal or change of drugs that potentially cause ES, are the most important preventive measures to prevent the development of drug-induced ES and status epilepticus.
Key words: epileptic seizures, drug-induced seizures, adverse drug reactions.
1. Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med 2002; 22 (3): 235–9.
2. Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000; 355 (9213): 1441–6.
3. Leppik IE, Birnbaum AK. Epilepsy in the elderly. Ann N Y Acad Sci 2010; 1184: 208–24.
4. Franson KL, Hay DP, Neppe V et al. Drug-induced seizures in the elderly. Causative agents and optimal management. Drugs Aging 1995; 7 (1): 38–48.
5. Парфенов В.А., Яхно Н.Н., Дамулин И.В. Нервные болезни. Частная неврология и нейрохирургия. М.: МИА, 2014.
[Parfenov V.A., Yakhno N.N., Damulin I.V. Nervous diseases. Private neurology and neurochirurgia. Moscow: MIA, 2014 (in Russian).]
6. Khan U, Seetharaman S, Merchant R. Neuroglycopenic Seizures: Sulfonylureas, Sulfamethoxazole, or Both? Am J Med 2017; 130 (1): e29–e30.
7. Legriel S, Azoulay E, Resche-Rigon M et al. Functional outcome after convulsive status epilepticus. Crit Care Med 2010; 38: 2295–303.
8. Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol 2016; 81 (3): 412–9.
9. Thundiyil JG, Rowley F, Papa L et al. Risk factors for complications of drug-induced seizures. J Med Toxicol 2011; 7: 16–23.
10. Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol 2007; 3: 15–9.
11. Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management 3rd edition. Bethesda, Md.: American Society of Health-System Pharmacists, 2018.
12. Jain KK. Drug-induced seizures. MedMerits Corporation. www.medmerits.com/index.php/article/drug_induced_seizures/P4
13. Ruffmann C, Bogliun G, Beghi E. Epileptogenic drugs: a systematic review. Expert Rev Neurother 2006; 6 (4): 575–89.
14. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 1999; 40 (Suppl. 10): 48–56.
15. Ebert U. Basic mechanisms of psychotropic drugs. Epilepsia 2002; 43 (Suppl. 2): 2–7.
16. De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992; 43 (Suppl. 2): 40–6.
17. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression. A perspective on seizures. Arch Gen Psychiatry 1986; 43 (1): 86–90.
18. Dunner DL, Zisook S, Billow AA et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59 (7): 366–73.
19. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50 (7): 256–61.
20. Johnston JA, Lineberry CG, Ascher JA et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52 (11): 450–6.
21. Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56 (9): 395–401.
22. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41 (3): 369–71.
23. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44 (12): 2247–9.
24. Camacho A, García-Navarro M, Martínez B et al. Olanzapine-induced myoclonic status. Clin Neuropharmacol 2005; 28 (3): 145–7.
25. Nakken KO, Johannessen SI. Seizure exacerbation caused by antiepileptic drugs. Tidsskr Nor Laegeforen 2008; 128 (18): 2052–5.
26. Spiller HA, Carlisle RD. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002; 40 (1): 81–90.
27. Gelisse P, Genton P, Kuate C et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45 (10): 1282–6.
28. Velioğlu SK, Gazioğlu S. Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy. Acta Neurol Scand 2007; 116 (2): 128–32.
29. De Oliveira Vilaça C, Orsini M et al. Seizures related to antibiotic use: update. BJSTR 2018; 4 (2): 3845–9.
30. Bhattacharyya S, Darby R, Berkowitz AL. Antibiotic-induced neurotoxicity. Curr Infect Dis Reps 2014; 16 (12): 448.
31. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin 1997; 13 (4): 741–62.
32. Saito T, Nakamura M, Watari M, Isse K. Tardive seizure and antibiotics: case reports and review of the literature. J ECT 2008; 24 (4): 275–6.
33. Darwish T. Ciprofloxacin-induced seizures in a healthy patient. N Z Med J 2008; 121 (1277): 104–5.
34. Sugimoto M, Uchida I, Mashimo T et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003; 45 (3): 304–14.
35. Calandra G, Lydick E, Carrigan J et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84 (5): 911–8.
36. Tack KJ, Smith JA. The safety profile of ofloxacin. Am J Med 1989; 87 (6C): 78S–81S.
37. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob. Agents Chemother 1994; 38 (3): 547–57.
38. Huang YT, Chen LA, Cheng SJ. Metronidazole-induced Encephalopathy: Case Report and Review Literature. Acta Neurol Taiwan 2012; 21 (2): 74–8.
39. Регистр лекарственных средств России, 2000.
[Registr lekarstvennykh sredstv Rossii, 2000 (in Russian).]
40. Choi EJ, Kang JK, Lee SA et al. New-onset seizures after liver transplantation: clinical implications and prognosis in survivors. Eur Neurol 2004; 52 (4): 230–6.
41. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24 (1): 38–47.
42. Calvet MC, Gresser I. Interferon enhances the excitability of cultured neurons. Nature 1979; 278 (5704): 558–60.
43. Pavlovsky L, Seiffert E, Heinemann U et al. Persistent BBB disruption may underlie alpha interferon-induced seizures. J Neurol 2005; 252 (1): 42–6.
44. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978; 93 (3): 516–8.
45. Walder B, Tramèr MR, Seeck M. Seizure-like phenomena and propofol: a systematic review. Neurology 2002; 58 (9): 1327–32.
46. Nieminen K, Westerèn-Punnonen S, Kokki H et al. Sevoflurane anaesthesia in children after induction of anaesthesia with midazolam and thiopental does not cause epileptiform EEG. Br J Anaesth 2002; 89 (6): 853–6.
47. Jääskeläinen SK, Kaisti K, Suni L et al. Sevoflurane is epileptogenic in healthy subjects at surgical levels of anesthesia. Neurology 2003; 61 (8): 1073–8.
48. Boison D. Methylxanthines, seizures, and excitotoxicity. In: J.E. Barrett, ed. Handbook of Experimental Pharmacology. Switzerland: Springer, 2011.
49. Odajima Y, Nakano H, Kato T, Okada K. Clinical review of patients with seizures that developed during theophylline administration – (III) Safety of theophylline examined in patients who had sequelae or died. Arerugi 2008; 57 (5): 536–42.
50. Klein KM, Shiratori K, Knake S et al. Status epilepticus and seizures induced by iopamidol myelography. Seizure 2004; 13 (3): 196–9.
51. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. Epilepsia 2006; 47 (7): 1094–120.
52. Johannessen Landmark C, Henning O, Johannessen SI. Proconvulsant effects of antidepressants – What is the current evidence? Epilepsy Behavior 2016; 61: 287–91.
53. Barry JD, Wills BK. Neurotoxic emergencies. Neurologic Clinics 2011; 29 (3): 539–63.
54. Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs 2015; 29 (2): 101–11.
55. Nakashima T, Tanaka T, Koido K et al. Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation. Int J Hematol 2019; 109 (6): 694–9.
56. Neal JM, Barrington MJ, Fettiplace MR et al. The third American Society of Regional Anesthesia and Pain Medicine practice advisory on local anesthetic systemic toxicity: executive summary 2017. Reg Anesth Pain Med 2018; 43 (2): 113–23.
________________________________________________
1. Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med 2002; 22 (3): 235–9.
2. Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000; 355 (9213): 1441–6.
3. Leppik IE, Birnbaum AK. Epilepsy in the elderly. Ann N Y Acad Sci 2010; 1184: 208–24.
4. Franson KL, Hay DP, Neppe V et al. Drug-induced seizures in the elderly. Causative agents and optimal management. Drugs Aging 1995; 7 (1): 38–48.
5. Parfenov V.A., Yakhno N.N., Damulin I.V. Nervous diseases. Private neurology and neurochirurgia. Moscow: MIA, 2014 (in Russian).
6. Khan U, Seetharaman S, Merchant R. Neuroglycopenic Seizures: Sulfonylureas, Sulfamethoxazole, or Both? Am J Med 2017; 130 (1): e29–e30.
7. Legriel S, Azoulay E, Resche-Rigon M et al. Functional outcome after convulsive status epilepticus. Crit Care Med 2010; 38: 2295–303.
8. Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol 2016; 81 (3): 412–9.
9. Thundiyil JG, Rowley F, Papa L et al. Risk factors for complications of drug-induced seizures. J Med Toxicol 2011; 7: 16–23.
10. Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol 2007; 3: 15–9.
11. Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management 3rd edition. Bethesda, Md.: American Society of Health-System Pharmacists, 2018.
12. Jain KK. Drug-induced seizures. MedMerits Corporation. www.medmerits.com/index.php/article/drug_induced_seizures/P4
13. Ruffmann C, Bogliun G, Beghi E. Epileptogenic drugs: a systematic review. Expert Rev Neurother 2006; 6 (4): 575–89.
14. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 1999; 40 (Suppl. 10): 48–56.
15. Ebert U. Basic mechanisms of psychotropic drugs. Epilepsia 2002; 43 (Suppl. 2): 2–7.
16. De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992; 43 (Suppl. 2): 40–6.
17. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression. A perspective on seizures. Arch Gen Psychiatry 1986; 43 (1): 86–90.
18. Dunner DL, Zisook S, Billow AA et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59 (7): 366–73.
19. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50 (7): 256–61.
20. Johnston JA, Lineberry CG, Ascher JA et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52 (11): 450–6.
21. Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56 (9): 395–401.
22. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41 (3): 369–71.
23. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44 (12): 2247–9.
24. Camacho A, García-Navarro M, Martínez B et al. Olanzapine-induced myoclonic status. Clin Neuropharmacol 2005; 28 (3): 145–7.
25. Nakken KO, Johannessen SI. Seizure exacerbation caused by antiepileptic drugs. Tidsskr Nor Laegeforen 2008; 128 (18): 2052–5.
26. Spiller HA, Carlisle RD. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002; 40 (1): 81–90.
27. Gelisse P, Genton P, Kuate C et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45 (10): 1282–6.
28. Velioğlu SK, Gazioğlu S. Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy. Acta Neurol Scand 2007; 116 (2): 128–32.
29. De Oliveira Vilaça C, Orsini M et al. Seizures related to antibiotic use: update. BJSTR 2018; 4 (2): 3845–9.
30. Bhattacharyya S, Darby R, Berkowitz AL. Antibiotic-induced neurotoxicity. Curr Infect Dis Reps 2014; 16 (12): 448.
31. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin 1997; 13 (4): 741–62.
32. Saito T, Nakamura M, Watari M, Isse K. Tardive seizure and antibiotics: case reports and review of the literature. J ECT 2008; 24 (4): 275–6.
33. Darwish T. Ciprofloxacin-induced seizures in a healthy patient. N Z Med J 2008; 121 (1277): 104–5.
34. Sugimoto M, Uchida I, Mashimo T et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003; 45 (3): 304–14.
35. Calandra G, Lydick E, Carrigan J et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84 (5): 911–8.
36. Tack KJ, Smith JA. The safety profile of ofloxacin. Am J Med 1989; 87 (6C): 78S–81S.
37. Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob. Agents Chemother 1994; 38 (3): 547–57.
38. Huang YT, Chen LA, Cheng SJ. Metronidazole-induced Encephalopathy: Case Report and Review Literature. Acta Neurol Taiwan 2012; 21 (2): 74–8.
39. Registr lekarstvennykh sredstv Rossii, 2000 (in Russian).
40. Choi EJ, Kang JK, Lee SA et al. New-onset seizures after liver transplantation: clinical implications and prognosis in survivors. Eur Neurol 2004; 52 (4): 230–6.
41. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24 (1): 38–47.
42. Calvet MC, Gresser I. Interferon enhances the excitability of cultured neurons. Nature 1979; 278 (5704): 558–60.
43. Pavlovsky L, Seiffert E, Heinemann U et al. Persistent BBB disruption may underlie alpha interferon-induced seizures. J Neurol 2005; 252 (1): 42–6.
44. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978; 93 (3): 516–8.
45. Walder B, Tramèr MR, Seeck M. Seizure-like phenomena and propofol: a systematic review. Neurology 2002; 58 (9): 1327–32.
46. Nieminen K, Westerèn-Punnonen S, Kokki H et al. Sevoflurane anaesthesia in children after induction of anaesthesia with midazolam and thiopental does not cause epileptiform EEG. Br J Anaesth 2002; 89 (6): 853–6.
47. Jääskeläinen SK, Kaisti K, Suni L et al. Sevoflurane is epileptogenic in healthy subjects at surgical levels of anesthesia. Neurology 2003; 61 (8): 1073–8.
48. Boison D. Methylxanthines, seizures, and excitotoxicity. In: J.E. Barrett, ed. Handbook of Experimental Pharmacology. Switzerland: Springer, 2011.
49. Odajima Y, Nakano H, Kato T, Okada K. Clinical review of patients with seizures that developed during theophylline administration – (III) Safety of theophylline examined in patients who had sequelae or died. Arerugi 2008; 57 (5): 536–42.
50. Klein KM, Shiratori K, Knake S et al. Status epilepticus and seizures induced by iopamidol myelography. Seizure 2004; 13 (3): 196–9.
51. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. Epilepsia 2006; 47 (7): 1094–120.
52. Johannessen Landmark C, Henning O, Johannessen SI. Proconvulsant effects of antidepressants – What is the current evidence? Epilepsy Behavior 2016; 61: 287–91.
53. Barry JD, Wills BK. Neurotoxic emergencies. Neurologic Clinics 2011; 29 (3): 539–63.
54. Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs 2015; 29 (2): 101–11.
55. Nakashima T, Tanaka T, Koido K et al. Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation. Int J Hematol 2019; 109 (6): 694–9.
56. Neal JM, Barrington MJ, Fettiplace MR et al. The third American Society of Regional Anesthesia and Pain Medicine practice advisory on local anesthetic systemic toxicity: executive summary 2017. Reg Anesth Pain Med 2018; 43 (2): 113–23.
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
3 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*ostroumova.olga@mail.ru
________________________________________________
Tatiana М. Ostroumova1, Elizaveta S. Akimova2, Aleksei I. Kochetkov3, Olga D. Ostroumova*3
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*ostroumova.olga@mail.ru